Background: Involvement of visceral organs usually dominates the clinical picture of
INTRODUCTION
Primary systemic amyloidosis is a chronic hematological disorder caused by plasma cell dyscrasia or B-cell lymphoproliferative disorders. Amyloid fibrils derived from immunoglobulin light chains (AL) gradually accumulate in multiple vital organs, including the heart, kidneys, liver, and gastrointestinal tract. Because of progressive dysfunction of these organs the prognosis of primary systemic AL amyloidosis is usually bad if left untreated [1] . High-dose melphalan with autologous peripheral blood stem cell transplantation (HDM/SCT) has been recently reported to show good therapeutic effects on both hematological response and organ function of the patients with this disease [2] [3] [4] , leading to an increase in their overall survival rate, although it remains controversial whether this treatment is truly superior to other intensive chemotherapies or not [5] . Peripheral nerves are also affected in patients with primary systemic AL amyloidosis and some of them manifest sensory-dominant polyneuropathy and/or autonomic dysfunction [6, 7] , but the detailed pathophysiological conditions of peripheral nerve impairment in this disease remain unclear.
In this study we retrospectively studied peripheral nerve involvement in primary systemic AL amyloidosis patients with regard to clinical findings, neurophysiological parameters including nerve conduction velocities and coefficients of variation of R-R intervals (CV R-R ), and their selected chemotherapies.
PATIENTS AND METHODS

Subjects
We retrospectively studied 43 primary systemic AL amyloidosis patients who had been consecutively admitted to our hospital between April 2002 and June 2008 (28 men and 15 women; age range, 43 to 71 years; mean, 57.0±7.3 years). None of the patients had received any medical treatments for plasma cell dyscrasia prior to being referred to us. The diagnosis of this type of amyloidosis was based on the criteria proposed by Gertz et al [8] . To detect amyloid deposition, conventional alkaline Congo red staining was performed in several biopsied tissues such as the kidney and the gastroduodenal or rectal mucosa, and in at least one of these specimens immunohistochemical staining was carried out using different antibodies to ALκ, ALλ, amyloid A, transthyretin and β2 microglobulin in order to confirm it as AL type [9] .
We obtained information on clinical findings including neurological examinations, results of electrophysiological studies, and treatments from the medical records of the patients. The presence of visceral organ involvement was assessed in each patient based on physical examinations and laboratory data, such as daily protein excretion in urine, hepatobiliary enzymes in serum and electro-and echocardiogram. Intensive chemotherapy for plasma cell dyscrasia, HDM/SCT, was performed according to our eligibility criteria [4] . To compare the results of electrophysiological studies, 20 age-matched healthy subjects (13 men and 7 women; age range, 45 to 68 years; mean, 56.0±5.9 years) were employed as controls. The Committee for Medical Ethics of Shinshu University School of Medicine approved this study.
Electrophysiological studies
Nerve conduction studies were carried out in median and tibial nerves. When clinical symptoms were not completely symmetrical, we selected the predominantly affected side. Terminal latency, negative amplitude of the compound muscle action potential (CMAP) and maximal motor conduction velocity (MCV) were measured and calculated in both median and tibial nerves. An active surface electrode was placed on the muscle belly and a reference electrode on the distal tendon to record CMAP of the abductor pollicis brevis muscle (APB) and abductor hallucis muscle (AH). The median nerve was stimulated at the wrist (7.0 cm proximal to the active recording electrode over the APB) and elbow. Tibial nerve was stimulated at the ankle (internal malleolus, 10.0 cm proximal to the active recording electrode over the AH) and knee (popliteal fossa).
To measure the maximal sensory nerve conduction velocity (SCV) of both the median and tibial nerves using common antidromic methods, pairs of surface recording electrodes were placed on the second finger and the third toe. Median and tibial nerves were stimulated in the same manner as for the motor conduction study. Peak to peak amplitude of sensory nerve action potential (SNAP) and SCV of both distal (finger-wrist or toe-ankle) and proximal (wrist-elbow or ankle-knee) parts were measured. When we could not evoke SNAP with antidromic methods using surface recording electrodes, we employed the near-nerve method. The stimulating surface ring electrodes were placed around the second finger and the third toe, and pairs of needle recording electrodes were insulated at the wrist, elbow, internal malleolus, and popliteal fossa. CV R-R on electrocardiogram was measured for evaluation of cardiac autonomic nerve function.
Statistics
To determine whether statistically significant differences existed, we used Student's t-test and Mann-Whitney's U test. A simple regression test was used for detection of a significant relationship between CV R-R and parameters of electrophysiological studies. The results represent the mean ± standard deviation where applicable, and a p-level less than 0.05 was considered to be statistically significant.
Commercially available statistics software was used for data analysis (StatView for Macintosh, Abacus Concepts, Berkeley, CA, USA).
RESULTS
Clinical and laboratory features
Fifteen patients (34.9%) of the 43 examined showed clinically apparent neuropathic symptoms due to peripheral nerve involvement. Their clinical profiles are shown in Table 1 . Nine were men and 6 were women. Age at diagnosis of peripheral nerve involvement and disease duration were 57.9±8.7 years and 14.7±7.2 months, respectively. Four patients showed neuropathic symptoms as a predominant clinical manifestation, while the remaining 11 presented with a mixture of visceral and neuropathic symptoms. Disease duration at diagnosis was 17.5±6.4 months in the former group and 13.7±7.5 months in the latter, although there was no significant difference between them. In the latter group clinical symptoms due to nephrotic syndrome and congestive heart failure frequently overshadowed the neuropathy. Ten had weight loss, general fatigue and light-headedness; 5 had edema, and the same number had dyspnea on exertion. Four complained of other symptoms, such as nausea, back pain, and hematuria. Physical examination revealed mild hepatomegaly in 2 patients, purpura in 2, macroglossia in 6, and pretibial edema in 7.
Laboratory data demonstrated abnormalities in all these 15 patients. Proteinuria was present in 12 patients, 5 of whom showed nephrotic syndrome. Three had serum creatinine levels greater than 1.5 mg/dl, and eight showed serum hemoglobin levels less [10] . To make a definite diagnosis of AL amyloidosis on immunohistochemical staining, renal biopsy was performed in 7 patients because of proteinuria. Other biopsy sites were gastroduodenum in 6 patients, rectum in 2, and gingival mucosa in 1. Sural nerve biopsy was performed in only one patient with polyneuropathy, and showed massive deposits of amyloid with a reduced number of myelinated nerve fibers. All amyloid deposits on these biopsied tissues were specifically immunolabeled by either anti-ALκ or AL λ antibody. 
Electrophysiological studies
Results of electrophysiological studies in primary systemic AL amyloidosis patients and controls are summarized in Table 2 . In the median nerve, whole patients and those with polyneuropathy showed a significant elongation of terminal latency and significant decreases in MCV, CMAP, distal SCV and SNAP compared with controls.
MCV, CMAP, proximal and distal SCV, and SNAP were significantly decreased and terminal latency was significantly longer also in the patients without clinically apparent neuropathic symptoms compared with controls. The patients with polyneuropathy tended to show lower levels of MCV, CMAP, SCV and SNAP than those without neuropathic symptoms, but there were no significant statistical differences between the two groups.
In the tibial nerve, whole patients and those with polyneuropathy showed significant decreases in MCV, CMAP and SCV compared with controls. Terminal latency was significantly longer in whole patients than in controls. The patients with polyneuropathy also showed a longer mean value of terminal latency compared with controls, although no significant differences between the two groups were present. The patients without neuropathic symptoms revealed a significant elongation of terminal latency and significant decreases in MCV, CMAP and proximal SCV compared with controls. The patients with polyneuropathy tended to show lower levels of MCV, CMAP and SCV than those without neuropathic symptoms, but there were no significant statistical differences between the two groups.
In the median nerve of the patients with bilateral CTS, MCV, CMAP, proximal and distal SCV, and SNAP showed lower levels and the mean value of terminal latency was longer compared with controls. No apparent change was present in the tibial nerve.
These findings were compatible with the clinical diagnosis of CTS. patients without it (57.1%) were treated with this intensive chemotherapy. Poor performance status due to disease progression was the most common reason why the remaining patients could not undergo HDM/SCT, and advanced age was the second.
With regard to the 4 patients showing polyneuropathy as a main disorder, 2 were treated with HDM/SCT, the details of which have been reported elsewhere [11] . However, the other 2 did not receive this treatment since both were in an almost bed-ridden state due to severe orthostatic hypotension. Eleven patients with peripheral neuropathy who were ineligible for HDM/SCT received other chemotherapies: VAD (vincristine, doxorubicin and dexamethasone) alone [12] in 5, M-dex (oral melphalan and large doses of dexamethasone) [13] in 4 and MP (oral melphalan and prednisolone) in 2. Vincristine has neurotoxicity as an adverse effect, but none of the patients treated with VAD showed apparent worsening of neuropathic symptoms.
DISCUSSION
Amyloid neuropathy is usually divided into two forms [14] : one is familial amyloid polyneuropathy (FAP), in which the precursor protein is transthyretin (TTR), and the other is peripheral nerve involvement associated with primary systemic AL amyloidosis. FAP with amyloid derived from TTR (ATTR) was once considered a disease peculiar to endemic areas, but FAP kindreds are now known to exist in many nations worldwide and ATTR-type FAP is recognized not to be a rare disease [15] . The clinical and pathophysiological similarity or difference among ATTR-type FAP and AL amyloidosis-related peripheral neuropathy is still incompletely understood. To address this clinical issue, amyloid typing is of basic importance. In this study we analyzed clinical symptoms and peripheral nerve parameters in AL amyloidosis patients, all of whom showed amyloid deposits specifically positive for either ALκ or ΑLλ with no immunoreactivity for ATTR irrespective of the presence of M-protein.
Clinical symptoms due to AL amyloid-induced peripheral nerve impairment in the present study consisted of polyneuropathy, bilateral CTS and autonomic dysfunction.
The mean age at diagnosis of peripheral nerve involvement was 57.9 years, and two thirds of the patients were male. Approximately one third of the whole patients examined in this study showed one or two of these neuropathic symptoms.
Polyneuropathy was seen in approximately one fourth of them and autonomic dysfunction was highly concurrent in these patients. This frequency was compatible with that of a previous report from another institute [1, 6] . A notable finding was the considerable similarity in the clinical picture of peripheral neuropathy between primary systemic AL amylodiosis and ATTR-type FAP. In the present study 11 patients were affected by polyneuropathy, which started in the legs with painful paresthesia and progressed in an ascending fashion, showing symmetrical and sensory-dominant impairment: all sensations were equally affected, and motor weakness and autonomic dysfunction appeared at an advanced stage. Within the autonomic dysfunction, orthostatic hypotension was the most common symptom, while severe digestive symptoms including periodic nausea and vomiting were not seen. The clinical phenotypes of ATTR-type FAP are reported to vary in different kindreds or individuals with diverse mutations of TTR genes [16, 17] : the presence of dissociated sensory loss (an initial and selective involvement of pain and thermal sensations) and autonomic failure at an early stage of the disease has been emphasized to be a cardinal feature in ATTR-type FAP patients from endemic foci [15, 18] . However, this is not seen in FAP patients from sporadic kindreds, even in those with ATTR Val30Met (methionine is substituted for valine at position 30 of TTR) showing a late age of onset and male predominance [15, 18] . Additionally, CTS is frequently associated with FAP patients irrespective of various TTR gene mutations [16, 19] . Thus, the overall clinical manifestations of peripheral neuropathy ascribed to primary systemic AL amyloidosis including the age of onset and sex ratio are very similar to those in ATTR-type FAP patients originating from non-endemic areas [15, 18] .
Another notable finding in the present study was that the peripheral nervous system seemed to be more extensively affected in the patients with this disease than was manifested clinically. In our series of patients neuropathic symptoms were seen at a frequency of approximately 35%: 11 patients with polyneuropathy commonly showed significant reduction of MCV, CMAP, SCV and SNAP in both median and tibial nerves, and 4 patients with clinically definite CTS showed decreases in both distal and proximal SCV of the median nerve, indicating diffuse deposition of AL amyloid on the peripheral nervous system in these patients [20] . Additionally in the patients without clinical manifestations of peripheral neuropathy, MCV and CMAP were obviously decreased in both median and tibial nerves compared with those of controls. SCV and SNAP in the median nerve were also significantly lower in these patients than in controls. CV R-R , which reflects cardiac parasympathetic nerve function [21] , showed a significant decrease both in the patients with apparent peripheral neuropathy and in those without, compared with controls: in approximately 60% of the whole patients abnormal values of CV R-R of less than 2.0% were observed irrespective of the presence of autonomic symptoms. All these results suggest that subclinical involvement of peripheral somatic and autonomic nerves is more frequent in primary systemic AL amyloidosis patients than previously reported [1, 6] and that electrophysiological examinations are useful for detecting these latent peripheral nerve lesions.
Finally, we emphasize that primary systemic AL amyloidosis is now a treatable disease [22] and that AL amyloidosis patients with peripheral neuropathy alone are the most suitable for intensive chemotherapy with HDM/SCT, targeting an underlying disorder such as plasma cell dyscrasia [23, 24] . A few patients who received this therapy have already shown recovery of peripheral neuropathy [11, 23, 24] , providing histopathological evidence of AL amyloid regression [11] . In the present study, however, HDM/SCT was performed in only 26.7% of the patients with peripheral neuropathy.
This figure is quite low in comparison with 57.1% in the patients without neuropathic symptoms. The most common reason why HDM/SCT was not performed in the patients with peripheral neuropathy was disease progression, and particularly in those with polyneuropathy poor performance status due to severe orthostatic hypotension made this treatment inapplicable. Eligibility for HDM/SCT in patients with primary systemic AL amyloidosis usually depends on visceral organ function, especially on preserved cardiac function [8] , but the present study has indicated that the severity of peripheral neuropathy including autonomic dysfunction is an important determinant in whether or not patients should undergo this risk-adapted chemotherapy. 
